PCORI is commissioning an interactive evidence map on therapeutic and device interventions for migraine prophylaxis. Migraine prevention arose as a topic of interest from a 2019 PCORI call for evidence synthesis topic nominations.
Migraine headache is a common, disabling condition that affects one in six Americans. Interventions for migraine prevention aim to decrease the number and severity of migraine headaches. Although drugs for migraine prevention have been used for at least several decades, recently, several newer interventions have received US Food and Drug Administration approval, including calcitonin-gene-related peptide antagonists and noninvasive devices.
This evidence review and map intends to visualize the volume of evidence on pharmacologic and device interventions for migraine prevention, and also to assess the impact of a selected set of newer migraine prevention interventions compared to interventions recommended in clinical practice guidelines and in common use. Specifically, the goal of these latter maps is to assess impact on migraine reduction and quality of life and describe reported intervention harms.
More to Explore...
Visualizing the Benefits and Harms of Drugs and Devices for Migraine Prevention
Migraine headache affects one in six Americans. For some people who live with them, migraines are a disabling condition. We’ve developed an evidence map, visualization, and report to help patients and healthcare professionals understand the results of studies on the many treatments available.